As I skim TFA, they say nobody who got the shot ended up getting HIV, which would be statistical anomaly for the population they tested.
They're not comparing the new treatment to nothing. They're comparing it to existing treatments.
> The shot was also superior to once-daily Truvada, another Gilead drug that is used for HIV prevention.
That's good news. As I understand it the existing treatments were already very good. And these injections are only once per year.
Probably quite a bit. The trial used the same dose of lenacapavir as what's used for maintenance in HIV patients; it's quite possible that less is needed to prevent infection in a healthy patient. Unfortunately, there's really no safe/ethical way for them to test lower doses.